Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 6
1997 13
1998 17
1999 23
2000 34
2001 56
2002 72
2003 111
2004 110
2005 144
2006 135
2007 147
2008 178
2009 152
2010 163
2011 188
2012 140
2013 129
2014 126
2015 118
2016 93
2017 106
2018 78
2019 63
2020 55
2021 60
2022 42
2023 37
2024 41
2025 45
2026 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,366 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial.
Jiang R, Zhao S, Wang R, Feng H, Zhang J, Li X, Mao Y, Yuan X, Fei Z, Zhao Y, Yu X, Poon WS, Zhu X, Liu N, Kang D, Sun T, Jiao B, Liu X, Yu R, Zhang J, Gao G, Hao J, Su N, Yin G, Zhu X, Lu Y, Wei J, Hu J, Hu R, Li J, Wang D, Wei H, Tian Y, Lei P, Dong JF, Zhang J. Jiang R, et al. JAMA Neurol. 2018 Nov 1;75(11):1338-1346. doi: 10.1001/jamaneurol.2018.2030. JAMA Neurol. 2018. PMID: 30073290 Free PMC article. Clinical Trial.
Nonsurgical treatments remain limited and ineffective. Our recent studies suggest that atorvastatin reduces hematomas and improves the clinical outcomes of patients with CSDH. OBJECTIVE: To investigate the safety and therapeutic efficacy of atorvastatin to nonsurgic …
Nonsurgical treatments remain limited and ineffective. Our recent studies suggest that atorvastatin reduces hematomas and improves th …
Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial.
Hong SJ, Lee YJ, Kang WC, Hong BK, Lee JY, Lee JB, Yang TH, Yoon J, Lee SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK; LODESTAR investigators. Hong SJ, et al. Cardiovasc Diabetol. 2024 Aug 7;23(1):287. doi: 10.1186/s12933-024-02386-w. Cardiovasc Diabetol. 2024. PMID: 39113067 Free PMC article. Clinical Trial.
BACKGROUND: The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-intensity statin therapy for coronary artery disease (CAD) remains to be clarified. This study aimed to evaluate the risk of NODM in patients w …
BACKGROUND: The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-int …
Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial.
Lee JE, Yu SH, Kim SR, Ahn KJ, Song KH, Lee IK, Shon HS, Kim IJ, Lim S, Kim DM, Chung CH, Lee WY, Lee SH, Kim DJ, Cho SR, Jung CH, Jeon HJ, Lee SH, Park KY, Rhee SY, Kim SG, Park SO, Kim DJ, Kim BJ, Lee SA, Kim YH, Kim KS, Seo JA, Nam-Goong IS, Lee CW, Kim DK, Kim SW, Cho CG, Kim JH, Kim YJ, Yoo JM, Min KW, Lee MK. Lee JE, et al. Diabetes Metab J. 2024 Jul;48(4):730-739. doi: 10.4093/dmj.2023.0077. Epub 2024 May 20. Diabetes Metab J. 2024. PMID: 38763510 Free PMC article. Clinical Trial.
One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). ...The combination group also showed …
One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metform …
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP; Ezetimibe Study Group. Ballantyne CM, et al. Circulation. 2003 May 20;107(19):2409-15. doi: 10.1161/01.CIR.0000068312.21969.C8. Epub 2003 Apr 28. Circulation. 2003. PMID: 12719279 Clinical Trial.
The primary efficacy end point was percentage reduction in LDL-C for pooled ezetimibe plus atorvastatin versus pooled atorvastatin treatment groups. Ezetimibe plus atorvastatin significantly improved LDL-C, HDL cholesterol (HDL-C), triglycerides, total choles …
The primary efficacy end point was percentage reduction in LDL-C for pooled ezetimibe plus atorvastatin versus pooled atorvastatin …
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Schwartz GG, et al. JAMA. 2001 Apr 4;285(13):1711-8. doi: 10.1001/jama.285.13.1711. JAMA. 2001. PMID: 11277825 Clinical Trial.
Likewise, there were no significant differences between the atorvastatin group and the placebo group in the incidence of secondary outcomes of coronary revascularization procedures, worsening heart failure, or worsening angina, although there were fewer strokes in the a …
Likewise, there were no significant differences between the atorvastatin group and the placebo group in the incidence of secondary ou …
Comparison of ezetimibe and atorvastatin versus atorvastatin alone on short-term major adverse cardiac events after percutaneous coronary intervention, a double-blind placebo-controlled randomized clinical trial.
Farshidi H, Bijani B, Sobhani SA, Dastsouz F, Abbaszadeh S. Farshidi H, et al. Trials. 2025 Mar 28;26(1):108. doi: 10.1186/s13063-025-08817-7. Trials. 2025. PMID: 40148971 Free PMC article. Clinical Trial.
This study aimed to compare the effect of ezetimibe and atorvastatin versus atorvastatin alone in short-term major cardiovascular events in patients after PCI in Bandar Abbas in 2018. ...Patients were randomly divided into two groups either to receive ezetimibe and …
This study aimed to compare the effect of ezetimibe and atorvastatin versus atorvastatin alone in short-term major cardiovascu …
Effect of Probucol and Atorvastatin Treatment on the Self-Care Ability of Acute Cerebral Infarction Patients: A Randomized Clinical Trial Study.
Yu N, Li Y, Han X, Sun Y, Li Y, Gao Y, Zhang X. Yu N, et al. Brain Behav. 2025 May;15(5):e70552. doi: 10.1002/brb3.70552. Brain Behav. 2025. PMID: 40356483 Free PMC article. Clinical Trial.
BACKGROUND: To investigate the effect of probucol and atorvastatin on self-care ability in patients with acute cerebral infarction (ACI). METHODS: Eighty-one patients with ACI admitted from November 2020 to May 2021 were divided into a combination treatment group (n = 40) …
BACKGROUND: To investigate the effect of probucol and atorvastatin on self-care ability in patients with acute cerebral infarction (A …
Clinical evaluation of photobiomodulation therapy and local 1.2% atorvastatin gel as an adjunct to subgingival instrumentation in patients with stage II periodontitis: a randomized controlled trial.
Ashokan DB, Shekar MK, Dharani K, Mani E, Pampani P, Ravichandran B. Ashokan DB, et al. Quintessence Int. 2025 Jul 21;56(7):514-527. doi: 10.3290/j.qi.b6218534. Quintessence Int. 2025. PMID: 40377185 Clinical Trial.
Group B: 30 patients (120 pocket sites) received 1.2% atorvastatin gel as local drug delivery. After application of the local drug, the treated periodontal pockets were secured with N-butyl-2-cyanoacrylate. ...CONCLUSION: The principal results of this study showed improved …
Group B: 30 patients (120 pocket sites) received 1.2% atorvastatin gel as local drug delivery. After application of the local drug, t …
The efficacy and long-term impact of different doses of statins in patients with acute coronary syndrome.
Chen H, Hao YM. Chen H, et al. J Physiol Pharmacol. 2024 Dec;75(6). doi: 10.26402/jpp.2024.6.02. Epub 2025 Feb 3. J Physiol Pharmacol. 2024. PMID: 39923225 Free article. Clinical Trial.
We aimed to evaluate the clinical efficacy of different doses of atorvastatin in patients with acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI). ...We assessed clinical parameters including blood lipid profiles, inflammatory marker levels, c …
We aimed to evaluate the clinical efficacy of different doses of atorvastatin in patients with acute coronary syndrome (ACS) followin …
Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment.
Xu Z, Fang Y, Peng Y, Zhang C, Zheng C. Xu Z, et al. J Cardiovasc Pharmacol Ther. 2025 Jan-Dec;30:10742484251361059. doi: 10.1177/10742484251361059. Epub 2025 Jul 23. J Cardiovasc Pharmacol Ther. 2025. PMID: 40702808 Clinical Trial.

All groups showed significant low-density lipoprotein cholesterol (LDL-C) reductions, with Group C (Alirocumab + Atorvastatin) having the largest decrease from 3.64 to 1.48 (P < .001). At 48 weeks, arterial lumen volumes increased in all groups, but Group C's was signif

…
All groups showed significant low-density lipoprotein cholesterol (LDL-C) reductions, with Group C (Alirocumab + Atorvastatin) having …
2,366 results